Clarified Precision Medicine Analysis
Overview
Clarified Precision Medicine, founded in 2021, is a pioneering firm in the realm of precision oncology. The company partners with oncologists, laboratories, life sciences entities, and payers to advance expertise in precision oncology. Their primary focus is on delivering comprehensive treatment guidance, disease monitoring, and early detection of cancer informed by molecular characteristics. The company is noted for offering scalable molecular tumor board services using a machine learning-based platform, making it a frontrunner in the integration of technology with medical expertise.
Leadership
- Rajni Natesan, MD, MBA: CEO with extensive C-suite experience in medical devices and health-tech, appointed in 2024.
- Lisa Alderson, MBA: Co-Founder and Strategic Advisor, renowned for her leadership in precision medicine ventures.
- Lincoln Nadauld, MD, PhD: Co-Founder and Senior Reviewer, expert in genomic testing and personalized medicine.
- Daniel Rotroff, PhD, MSPH: Chief Technology Officer, leading technological advancements leveraging data-driven insights.
- Howard McLeod, PharmD, FASCO, FCCP: Co-Founder and Medical Director, a national figure in precision oncology and genomic-guided therapies.
- Richard Schilsky, MD, MBA: Managing Board Member, former Chief Medical Officer at ASCO, brings extensive oncology expertise.
Strategic Partnerships and Collaborations
Clarified Precision Medicine has established significant strategic partnerships, notably with xCures, to enhance clinical decision support through AI. This collaboration is geared towards extracting relevant patient data to generate actionable treatment recommendations. The company also collaborates with organizations like VieCure to incorporate precision testing tools within their platforms, aiming to promote guidelines-based precision oncology.
Financial Overview
In April 2024, the company secured $1.2 million in seed funding, reflecting market confidence in its potential to address precision oncology challenges. Investors include Joyance Partners.
Recent Developments and Future Outlook
Clarified Precision Medicine continues to innovate in precision oncology, focusing on closing the "last mile" gap by advancing targeted and personalized treatments. The firm emphasizes leveraging artificial intelligence and molecular insights to redefine cancer care, with their molecular tumor board services and strategic collaborations positioning them as a leader in this space.
Contact Information
- Headquarters Address: 447 Sutter St., Suite 405 PMB13, San Francisco, CA 94108
- Email: info@clarifiedmedicine.com
- Telephone: 435.288.0640
Competitor Profiling
Key Competitors
1. Mamotest
- Location: Distrito Federal, Argentina
- Specialty: Breast cancer detection and diagnosis utilizing AI.
- Funding: Raised US $5M, with a US $1.5M round led by the Philips Foundation.
2. knownwell
- Location: Boston, MA
- Field: Weight-inclusive healthcare services.
- Funding: Secured US $24.5M; recent Series A of US $20M from Andreessen Horowitz.
- Expansion: Announced new clinics in Chicago, expanding healthcare offerings.
3. Perthera
- Platform: Offers the Perthera Precision Oncology Platform, AI-driven.
- Objective: Enhances cancer care with precise, individualized treatment recommendations.
4. Caris Life Sciences
- Specialization: Advanced molecular profiling and data analysis.
- Impact: Over half a million cancer patients benefited globally.
5. Exact Sciences
- Focus: Cancer eradication through early detection and personalized treatment.
- Contribution: Cologuard and Oncotype DX tests have revolutionized diagnostics and treatment.
Analysis
Clarified Precision Medicine faces a competitive landscape with companies leveraging AI and molecular science in precision oncology. Competitors like Mamotest and knownwell specialize in niche healthcare segments, while Perthera, Caris Life Sciences, and Exact Sciences focus on advanced diagnostics and tailored treatments. Clarified Precision Medicine's distinct value proposition lies in its cutting-edge Molecular Tumor Board, establishing a unique position in the precision medicine market.
